Maintenance IVIg therapy in myasthenia gravis does not affect disease activity

Journal of the Neurological Sciences

Volumn 338, Issue 1-2, 2014, Pages 39-42

  Hellmann, M A ^a   Mosberg Galili, R ^a   Lotan, I ^a   Steiner, I ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cost effective; Immune suppression; Immuno modulation; Immunotherapy; IVIg; Myasthenia gravis; Remission

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; PREDNISONE; PYRIDOSTIGMINE;

ADULT; ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HEADACHE; HEART INFARCTION; HUMAN; IMMUNOTHERAPY; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; THYMECTOMY;

COST EFFECTIVE; IMMUNE SUPPRESSION; IMMUNO-MODULATION; IMMUNOTHERAPY; IVIG; MYASTHENIA GRAVIS; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, CHOLINERGIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896708772     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.10.043     Document Type: Article

References (22)

1. D.P. Richman, and M.A. Agius Treatment principles in the management of autoimmune myasthenia gravis Ann N Y Acad Sci 998 2003 457 472
2. I.K. Hart, S. Sathasivam, and T. Sharshar Immunosuppressive agents for myasthenia gravis Cochrane Database Syst Rev 4 2007 CD005224
3. P. Imbach, S. Barandun, V. d'Apuzzo, C. Baumgartner, A. Hirt, and A. Morell et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood Lancet 8232 1981 1228 1231
4. S. Sathasivam Current and emerging treatments for the management of myasthenia gravis Ther Clin Risk Manag 7 2011 313 323
5. O. Hilkevich, V.E. Drory, J. Chapman, and A.D. Korczyn The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis Clin Neuropharmacol 24 2001 173 176
6. A. Achiron, Y. Barak, S. Miron, and I. Sarova-Pinhas Immunoglobulin treatment in refractory myasthenia gravis Muscle Nerve 23 2000 551 555
7. P. Gajdos, S. Chevret, and K.V. Toyka Intravenous immunoglobulin for myasthenia gravis Cochrane Database Syst Rev 12 2012 CD002277
8. J.T. Guptill, B.K. Sharma, A. Marano, A. Soucy, A. Krueger, and D.B. Sanders Estimated cost of treating myasthenia gravis in an insured U.S. population Muscle Nerve 45 2012 363 366
9. A. Jaretzki III, R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, and A.S. Penn et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America Neurology 55 2000 16 23
10. B. Efron Bootstrap methods: another look at the jackknife Ann Stat 7 1979 1 26
11. C.M. Wiles, P. Brown, H. Chapel, R. Guerrini, R.A. Hughes, and T.D. Martin et al. Intravenous immunoglobulin in neurological disease: a specialist review J Neurol Neurosurg Psychiatry 72 2002 440 448
12. P. Gajdos, S. Chevret, B. Clair, C. Tranchant, and C. Chastang Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis Ann Neurol 41 1997 789 796
13. P. Gajdos, C. Tranchant, and B. Clair et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin - a randomized double-blind clinical trial Arch Neurol 62 2005 1689 1693
14. L. Zinman, E. Ng, and V. Bril IV immunoglobulin in patients with myasthenia gravis - a randomized controlled trial Neurology 68 2007 837 841
15. J. Ronager, M. Ravnborg, I. Hermansen, and S. Vorstrup Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis Artif Organs 25 2001 967 973
16. G.I. Wolfe, R.J. Barohn, B.M. Foster, C.E. Jackson, J.T. Kissel, and J.W. Day et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis Muscle Nerve 26 2002 549 552
17. B. Wegner, and I. Ahmed Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis Clin Neurol Neurosurg 105 2002 3 8
18. H.J. Oosterhuis Observations of the natural history of myasthenia gravis and the effect of thymectomy Ann N Y Acad Sci 377 1981 678 690
19. G.S. Gronseth, and R.J. Barohn Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 55 2000 7 15
20. C. Schneider-Gold, P. Gajdos, K.V. Toyka, and R.R. Hohlfeld Corticosteroids for myasthenia gravis Cochrane Database Syst Rev 2 2005 CD002828
21. J.M. Heckmann, E.B. LeePan, and R.W. Eastman High-dose immunosuppressive therapy in generalised myasthenia gravis - a 2-year follow-up study S Afr Med J 91 2001 765 770
22. R. Hohlfeld, K.V. Toyka, U.A. Besinger, B. Gerthold, and K. Heininger Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine Ann Neurol 17 1985 238 242